China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Nvidia Options Price in $280 Billion Earnings Swing 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Tesla Raises Cybertruck Prices by $5,000 in US 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Add as a preferred source on Google
CAMBRIDGE, Mass., May 01, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA, on Tuesday, May 8, 2018 at 3:30 p.m. ET.
A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 60 days following the presentation.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
[email protected]
617-680-1088
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia
[email protected]
212-362-1200
